Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest (BATS: BTCO)

Ultime notizie per Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest (BATS:BTCO)

The Trusts investment objective is to reflect the performance of the spot price of bitcoin as measured using the Lukka Prime Bitcoin Reference Rate (the Benchmark), less the Trusts and other liabilities.

Invesco Galaxy Bitcoin ETF

DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) ("DatChat" or the "Company"), a secure messaging and social media company, today announced that the Canadian Patent Office has granted Canadian Patent No. 3,149,004, titled "Systems And Methods Of Transforming Electronic Content."
DatChat's "Systems And Methods Of Transforming Electronic Content" is already patented in many important countries including the United States. DatChat recently received a Notice of Allowance from the Mexican and European Patent Offices for the same invention. In total, the Company's IP portfolio now includes 17 issued patents, 1 Notice of Allowance and several filed international patent applications.

News

DATS

DatChat Secures Canadian Patent For "Systems And Methods Of Transforming Electronic Content"

JP Morgan analyst Matthew Boss maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Overweight and raises the price target from $40 to $46.

Price Target

Analyst Ratings

BBWI

JP Morgan Maintains Overweight on Bath & Body Works, Raises Price Target to $46

Management

TLYS

Tilly's Appoints Nate Smith As President, CEO, And Director Effective August 18, 2025; Co-Founder Hezy Shaked To Transition Solely To Executive Chairman Role

JP Morgan analyst Matthew Boss maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and raises the price target from $78 to $88.

URBN

JP Morgan Maintains Overweight on Urban Outfitters, Raises Price Target to $88

Interim results from the CARE PMR study support the use of ultra-low-field MRI as a triage tool for monitoring patients on amyloid-targeting therapies.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fhyperfinemri.com&amp;esheet=54297297&amp;newsitemid=20250728550140&amp;lan=en-US&amp;anchor=Hyperfine%2C+Inc&amp;index=1&amp;md5=ffae40a144ecfce17b53a96017c7b420">Hyperfine, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop&#xAE; system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada.
Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients undergoing Lecanemab therapy. Participants were scanned using the Swoop&#xAE; system within one week of their clinical high-field MRI scans, as part of the safety monitoring protocol required by the FDA when it approved Lecanemab.
The Swoop&#xAE; system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Researchers note that while ultra-low-field MRI is promising as a triage tool to screen for ARIA-E, high-field MRI may remain necessary for comprehensive evaluation in some cases.

Biotech

General

HYPR

Hyperfine's Portable MRI Shows 100% Sensitivity For ARIA-E in Alzheimer's Patients On Lecanemab, Supporting Use As Triage Tool In CARE PMR Study

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.25%</li>
<li>Morgan Stanley analyst David Arcaro maintained an Underweight rating and slashed the price target from $52 to $51 on June 18, 2025. This analyst has an accuracy rate of 70%.</li>
<li>JP Morgan analyst Richard Sunderland maintained a Neutral rating and cut the price target from $75 to $71 on May 19, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On June 25, board of directors of Edison International declared a quarterly common stock dividend of 82.75 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest EIX <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0728">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0728"><img loading="lazy" decoding="async" width="911" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045430/image-421.png" alt="" class="wp-image-1002872" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045430/image-421.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045430/image-421-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045430/image-421-768x701.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Northwest Natural Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.80%</li>
<li>Stifel analyst Selman Akyol maintained a Buy rating and raised the price target from $45 to $49 on June 13, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Wells Fargo analyst Sarah Akers maintained an Equal-Weight rating and raised the price target from $45 to $47 on May 7, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: NW Natural Holdings will post second quarter earnings on Tuesday, Aug. 5.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest NWN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0728">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0728"><img loading="lazy" decoding="async" width="916" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045503/image-422.png" alt="" class="wp-image-1002875" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045503/image-422.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045503/image-422-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045503/image-422-768x698.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.52%</li>
<li>B of A Securities analyst Julien Dumoulin-Smith maintained a Neutral rating and raised the price target from $62 to $67 on July 21, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Mizuho analyst Paul Fremont maintained an Outperform rating and increased the price target from $68 to $72 on June 25, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: Eversource Energy will report financial results for the second quarter on Friday, Aug. 1.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest ES <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0728">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0728"><img loading="lazy" decoding="async" width="911" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045549/image-423.png" alt="" class="wp-image-1002877" style="width:521px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045549/image-423.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045549/image-423-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28045549/image-423-768x700.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46653283/sp-500-notches-5th-consecutive-record-close-following-strong-earnings-investor-sentiment-edges-lower-but-fear-index-remains-in-greed-zone">S&amp;P 500 Notches 5th Consecutive Record Close Following Strong Earnings: Investor Sentiment Edges Lower, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

Earnings

Long Ideas

Dividends

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Utilities Delivering High-Dividend Yields

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Justin Lake downgraded the rating for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Peer Perform. HCA Healthcare shares closed at $334.32 on Friday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss downgraded the rating for American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) from Neutral to Underweight and maintained the price target of $9. American Eagle shares closed at $11.74 on Friday. <a href="https://www.benzinga.com/quote/AEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Amit Daryanani downgraded Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Outperform to In-Line and maintained the price target of $72. Cisco shares closed at $68.69 on Friday. <a href="https://www.benzinga.com/quote/CCSO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Jeffrey Stevenson downgraded Core &amp; Main, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) from Buy to Hold and maintained the price target of $68. Core &amp; Main shares closed at $65.77 on Friday. <a href="https://www.benzinga.com/quote/CNM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Derek Podhaizer downgraded the rating for Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) from Overweight to Neutral and maintained the price target of $25. Halliburton shares closed at $22.45 on Friday. <a href="https://www.benzinga.com/quote/HAL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/quote/CSCO/analyst-ratings"><img decoding="async" src="blob:https://editorial.benzinga.com/cf9c88eb-6434-44ed-93ff-f94b8c6aebca" alt="" style="width:582px;height:auto" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46655271/top-3-health-care-stocks-that-may-explode-in-july">Top 3 Health Care Stocks That May Explode In July</a></li>
</ul>
Photo via Shutterstock

Downgrades

CSCO

This Cisco Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $29 price target.

Reiteration

CELC

Needham Reiterates Buy on Celcuity, Maintains $29 Price Target

Maris-Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>, MTEKW))) ("Maris-Tech" or the "Company"), a global leader in video and artificial intelligence ("AI") - based edge computing technology, today announced that it has received a $144,000 order. The order, placed by a customer in the defense industry, is for the design and development of an advanced tactical video and AI-based platform.
The new product will be based on Maris-Tech's Jupiter-AI miniature edge computing solution, which is known for its low power consumption, compact size, and robust performance in mission-critical environments. The platform will be designed to support both day and thermal video sensors and to meet the extreme operational requirements needed in modern tactical warfare.
The design and the development of Maris-Tech's new product are expected to enhance real-time situational awareness and decision-making capability for tactical units operating in harsh field conditions.
"This is another step in our transition to supplying comprehensive products to the defense market, particularly in the field of tactical devices," said Israel Bar, Chief Executive Officer of Maris-Tech. "We believe this order both validates the strength of our Jupiter-AI platform and reflects a growing confidence in our ability to deliver rugged, high-performance systems that respond to today's defense needs."

Contracts

MTEK

Maris-Tech Announces It Has Secured A $144K Order From A Defense Industry Customer For The Design And Development Of An Advanced Tactical Video And AI Based Platform

JP Morgan analyst Matthew Boss maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Overweight and raises the price target from $141 to $151.

JP Morgan Maintains Overweight on Abercrombie & Fitch, Raises Price Target to $151

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Shares of ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet<a href="https://www.benzinga.com/quote/ATAI"> its primary endpoint.</a>
ATAI Life Sciences shares dipped 9.3% to $3.23 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) declined 9.2% to $6.29 in pre-market trading. Fusion Fuel Green shares jumped 47% on Friday after the company announced its subsidiary has confirmed several new projects.</li>
<li>Revvity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NASDAQ">RVTY</a>) fell 7.4% to $96.00 in pre-market trading as the company lowered its FY2025 earnings guidance.</li>
<li>KB Financial Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) shares declined 5.1% to $81.50 in pre-market trading after declining 5% on Friday.</li>
<li>Rapport Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) fell 4.9% to $15.27 in pre-market trading after falling 3% on Friday.</li>
<li>Metsera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) declined 4.9% to $38.50 in pre-market trading.</li>
<li>Volcon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) fell 4.6% to $12.79 in pre-market trading.</li>
<li>Shinhan Financial Group Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHG#NYSE">SHG</a>) fell 4.6% to $48.59 in pre-market trading. On Friday, Shinhan Financial Group posted second-quarter earnings of $2.19 per share on sales of $2.048 billion.</li>
<li>Cantor Equity Partners I Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEPO#NASDAQ">CEPO</a>) tumbled 4.3% to $11.35 in pre-market trading.</li>
<li>Quantumscape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) fell 3.6% to $11.54 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46655271/top-3-health-care-stocks-that-may-explode-in-july">Top 3 Health Care Stocks That May Explode In July</a></li>
</ul>
Photo via Shutterstock

Movers

ATAI

CEPO

HTOO

MTSR

RAPP

RVTY

VLCN

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Baird analyst Catherine Schulte maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Outperform and raises the price target from $17 to $18.

AVTR

Baird Maintains Outperform on Avantor, Raises Price Target to $18

CTSH

LINE

Cognizant Technology Solutions Partners With Lineage For Customer Service Transformation

GFAI

Guardforce AI Launches Smart Solutions And AI Applications At Rebranding Event Hosted By Thai Subsidiary, Guardforce Cash Solutions Security In Bangkok

Baird analyst Timothy Wojs maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Outperform and raises the price target from $130 to $142.

Baird Maintains Outperform on Mohawk Industries, Raises Price Target to $142

Upon the closing of the Private Placement, Mill City will adopt a Sui Treasury Strategy
Mill City intends to continue its short-term non-bank lending and specialty finance business
Marius Barnett and Stephen Mackintosh, Co-founders of Karatage, will become Chairman of the Board of Directors of the Company and Chief Investment Officer of the Company, respectively, effective upon the closing of the Private Placement
Industry-First Relationship with Sui Foundation Provides Institutional-Grade Gateway for Exposure to Only Blockchain Built for Mass Adoption
Mill City Ventures III, Ltd. ("Mill City" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>), a non-bank lender and specialty finance company, today announced that it has entered into securities purchase agreements (the "Securities Purchase Agreements") for a private investment in public equity for the purchase and sale of 83,025,830 shares of common stock (or common stock equivalents in lieu thereof) at a price of $5.42 per share for expected aggregate gross proceeds of approximately $ 450,000,000, before deducting placement agent fees and other offering expenses (the "Private Placement", or the "Offering").
Karatage Opportunities ("Karatage"), the London-based proprietary hedge fund specializing in digital assets and emerging technology investments, founded by Marius Barnett and Stephen Mackintosh, acted as the lead investor, with an equivalent investment from the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. As a significant early investor in the Sui ecosystem, Karatage has established itself as a strategic partner to Mysten Labs, the original contributors to Sui, with deep operational experience across the Sui network.
The Offering included participation by prominent firms and infrastructure providers Big Brain Holdings, Galaxy Digital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) and Dr Jack Kong – NLABS Fund as well as investment from Pantera Capital , M2, Electric Capital, GSR, Selini, Protagonist, ParaFi Capital, Borderless, dao5, Arrington Capital, Comma3 Ventures, FalconX, Paper Ventures and Maven 11 amongst others. Galaxy Asset Management will serve as the Asset Manager.
The closing of the Offering is expected to occur on or about July 31, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use approximately 98% of the net proceeds from the Private Placement to acquire the native cryptocurrency of the Sui blockchain commonly referred to as "SUI", and approximately 2% of the net proceeds from the Private Placement to fund the Company's short-term lending business. SUI will serve as the Company's primary treasury reserve asset.
A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the offering.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

GLXY

MCVT

Mill City Ventures Announces $450M Private Placement Of 83M Shares At $5.42/Share; Will Adopt Sui Treasury Strategy, Invest 98% In SUI Token

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) will release earnings results for the second quarter before the opening <a href="https://www.benzinga.com/quote/MRK/earnings">bell on Tuesday, July 29.</a>
Analysts expect the health care company to report quarterly earnings at $2.03 per share, down from $2.28 per share in the year-ago period. Merck projects to report quarterly revenue at $15.87 billion, compared to $16.11 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
With the recent buzz around Merck, some investors may be eyeing potential gains from the company's dividends. Merck offers an annual dividend yield of 3.82% — a quarterly dividend amount of 81 cents per share ($3.24 a year).
To figure out how to earn $500 monthly from Merck, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Merck's $3.24 dividend: $6,000 / $3.24 = 1,852 shares.
So, an investor would need to own approximately $156,883 worth of Merck, or 1,852 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $3.24 = 370 shares, or $31,343 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis; the dividend payment and the stock price fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
MRK Price Action: Shares of Merck rose by 0.7% to close at $84.71 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Image: Shutterstock

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chargepoint.com%2F&amp;esheet=54297266&amp;newsitemid=20250727351893&amp;lan=en-US&amp;anchor=ChargePoint&amp;index=1&amp;md5=d2bf6c9ef6d93e86152f2ae96ddff240">ChargePoint</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>), a leading provider of EV charging solutions, announced that today the Company implemented a reverse stock split of its common stock at a ratio of 1-for-20, which will be reflected at market open. The reverse stock split is intended to increase the market price per share of the Company's common stock and help the Company comply with the minimum trading price criteria for continued listing on the New York Stock Exchange (the "NYSE").
On July 8, 2025, ChargePoint shareholders approved a reverse stock split ratio within a range of 1-for-2 to 1-for-30 at the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting") and authorized the Company's Nominating and Corporate Governance Committee to determine and execute the final ratio. The Company's Nominating and Corporate Governance Committee subsequently approved the final reverse split ratio of 1-for-20.
The reverse stock split will not modify any rights or preferences of the Company's common stock. The trading symbol for the Company's common stock will remain "CHPT." The new CUSIP number for the Company's common stock following the reverse stock split will be 15961R 303 and the new ISIN number will be US15961R3030.
Effective as of 12:01 am Eastern Time today, July 28, 2025, every twenty (20) issued and outstanding shares of the Company's common stock have been converted into one share of the Company's common stock.
The reverse stock split will affect all shareholders uniformly and will not affect any shareholder's percentage ownership interest in the Company (except to the extent that the reverse stock split would result in any of the shareholders owning a fractional interest). Shareholders who otherwise would be entitled to receive fractional shares will receive a cash payment in lieu of such fractional shares.
Stockholders who hold their shares in "street name" that is through a brokerage firm, bank, dealer or other similar organization, will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular processes, and do not need to take any action in connection with the reverse stock split. Stockholders of record will be receiving information from Continental Stock Transfer &amp; Trust Company, the Company's transfer agent, regarding their stock ownership following the reverse stock split.
Additional information regarding the reverse stock split and other matters voted on at the Annual Meeting can be found in the Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2025, and on ChargePoint's Investor Relations website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.chargepoint.com%2Foverview%2Fdefault.aspx&amp;esheet=54297266&amp;newsitemid=20250727351893&amp;lan=en-US&amp;anchor=investors.chargepoint.com&amp;index=2&amp;md5=61afe99c5a40371d9d5df64dff07a22c">investors.chargepoint.com</a>.
&nbsp;

Stock Split

CHPT

ChargePoint Announces 1-For-20 Reverse Stock Split, Effective July 28, 2025

Baird analyst Michael Bellisario maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Neutral and raises the price target from $148 to $150.

Baird Maintains Neutral on Hyatt Hotels, Raises Price Target to $150

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest

Invesco Galaxy Bitcoin ETF Beneficial Interest

Comments

Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest

Notizie

Ultime notizie per Invesco Galaxy Bitcoin ETF Common Shares of Beneficial Interest (BATS:BTCO)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO